Evidence map›Paper›PMID 36716323›Full record

ArticlePLoS biology2023

Early transcriptional and epigenetic divergence of CD8+ T cells responding to acute versus chronic infection.

Lauren K Quezada, Wenhao Jin, Yi Chia Liu, Eleanor S Kim, Zhaoren He, Cynthia S Indralingam, Tiffani Tysl, Lara Labarta-Bajo, Ellen J Wehrens, Yeara Jo and 5 more

Open access · goldAbstract read
In one paragraph

Article in PLoS biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Renaissance of antiviral CD8Nature reviews. Immunology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. A Dapl1Science advances · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. CD8Immunity · 2023
    Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Lauren K QuezadaDepartment of Medicine, University of California San Diego, La Jolla, California, United States of America.
Wenhao JinDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, United States of America.
Yi Chia LiuDepartment of Medicine, University of California San Diego, La Jolla, California, United States of America.
Eleanor S KimDepartment of Medicine, University of California San Diego, La Jolla, California, United States of America.
Zhaoren HeDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, United States of America.
Cynthia S IndralingamDepartment of Medicine, University of California San Diego, La Jolla, California, United States of America.
Tiffani TyslDepartment of Medicine, University of California San Diego, La Jolla, California, United States of America.
Lara Labarta-BajoDivision of Biological Sciences, University of California San Diego, La Jolla, California, United States of America.
Ellen J WehrensDivision of Biological Sciences, University of California San Diego, La Jolla, California, United States of America.
Yeara JoDivision of Biological Sciences, University of California San Diego, La Jolla, California, United States of America.
Katelynn R KazaneDivision of Biological Sciences, University of California San Diego, La Jolla, California, United States of America.
Christopher HattoriDivision of Biological Sciences, University of California San Diego, La Jolla, California, United States of America.
Elina I ZunigaDivision of Biological Sciences, University of California San Diego, La Jolla, California, United States of America.
Gene W YeoDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, United States of America.
John T ChangDepartment of Medicine, University of California San Diego, La Jolla, California, United States of America.ORCID 0000-0003-0873-6218
University of California San Diego · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PETER J TONTONOZ · 2003 to 2026
$40.4M
Functional RNA elements in the human genomeR01HG004659 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Kevin Daniel Corbett, Eugene Wei-Ming Yeo · 2008 to 2026
$12.4M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LARS ECKMANN, Bernd G. Schnabl · 2019 to 2026
$10.8M
Single-Cell Transcriptomic and Epigenetics CoreP01AI132122 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZUNIGA, ELINA I · 2018 to 2022
$9.8M
Positive Immune-regulators During Chronic Viral InfectionsR01AI113923 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZUNIGA, ELINA I · 2015 to 2024
$5.1M
Using single-cell RNA-seq to interrogate host immunity to pathogensR01AI123202 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHANG, JOHN T, YEO, EUGENE WEI-MING · 2016 to 2020
$3.1M
Molecular Mechanisms Underlying Dendritic Cell Adaptations During Chronic InfectionR01AI145314 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZUNIGA, ELINA I · 2020 to 2024
$2.4M
Role of proteasome activity in adaptive immunityR01AI129973 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHANG, JOHN T · 2018 to 2022
$2.2M
Illumina NovaSeq 6000 Sequencing SystemS10OD026929 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEPSEN, KRISTEN LYNN · 2019 to 2019
$600k
BLRD VA I01 BX005106CSRD VA I01 CX002396NCI NIH HHS P30 CA023100NHGRI NIH HHS R01 HG004659NIAID NIH HHS P01 AI132122NIAID NIH HHS R01 AI113923NIAID NIH HHS R01 AI123202NIAID NIH HHS R01 AI129973NIAID NIH HHS R01 AI145314NIDDK NIH HHS P30 DK063491NIDDK NIH HHS P30 DK120515NIH HHS S10 OD026929
6 · The paper itself

Abstract

During a microbial infection, responding CD8+ T cells give rise to effector cells that provide acute host defense and memory cells that provide sustained protection. An alternative outcome is exhaustion, a state of T cell dysfunction that occurs in the context of chronic infections and cancer. Although it is evident that exhausted CD8+ T (TEX) cells are phenotypically and molecularly distinct from effector and memory CD8+ T cells, the factors regulating the earliest events in the differentiation process of TEX cells remain incompletely understood. Here, we performed single-cell RNA-sequencing and single-cell ATAC-sequencing of CD8+ T cells responding to LCMV-Armstrong (LCMV-Arm) or LCMV-Clone 13 (LCMV-Cl13), which result in acute or chronic infections, respectively. Compared to CD8+ T cells that had undergone their first division in response to LCMV-Arm (Div1ARM) cells, CD8+ T cells that had undergone their first division in response to LCMV-Cl13 (Div1CL13) expressed higher levels of genes encoding transcription factors previously associated with exhaustion, along with higher levels of Ezh2, the catalytic component of the Polycomb Repressive Complex 2 (PRC2) complex, which mediates epigenetic silencing. Modulation of Ezh2 resulted in altered expression of exhaustion-associated molecules by CD8+ T cells responding to LCMV-Cl13, though the specific cellular and infectious contexts, rather than simply the level of Ezh2 expression, likely determine the eventual outcome. Taken together, these findings suggest that the differentiation paths of CD8+ T cells responding to acute versus chronic infections may diverge earlier than previously appreciated.

Indexed as

Lymphocytic ChoriomeningitisAnimalsCD8-Positive T-LymphocytesEpigenesis, GeneticHumansLymphocytic choriomeningitis virusMiceMice, Inbred C57BLPersistent Infection

Identifiers

PMID36716323
PMCPMC9886247
OpenAlexW4318580160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.